Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone and Vitamin B Complex in Post-COVID-19 Syndrome
NCT05638633Phase 3Completed
- Start
- Nov 2022
- Primary completion
- Jan 2025
- Modality
- Implantable Devices, Transdermal Patches, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prednisolone and Neurovit Forte in Post COVID-19 Syndrome (PCS) (4 arms). Primary endpoints: Proportion of participants retained after 28 days and Mean difference in PROMIS Total Score at 28 days. Started Nov 2022; status: completed.
02
Drugs
prednisoloneNeurovit Forte
03
Conditions
Post COVID-19 Syndrome (PCS)
Beyond the preview
Go deeper on NCT05638633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638633.